US hospital conducts a clinical trial of Safe Emergency Department dIscharGe Rate
Photo by Robina Weermeijer
Hennepin Healthcare Research Institute is enrolling patients into the clinical trial investigating Safe Emergency Department dIscharGe Rate.
The Siemens POC High Sensitivity Troponin-I Test System is an in vitro diagnostic test for the quantitative measurement of cardiac troponin I (cTn-I) in fresh human capillary (fingerstick) whole blood, and lithium-heparinized venous whole blood or plasma, to be used by healthcare professionals at the point of care (POC) as well as in the clinical laboratory.
The Siemens POC High Sensitivity Troponin-I Test System is to be used as an aid in the diagnosis of myocardial infarction (MI).
The trial is designed to enroll male and female 21 years and older and is being conducted in the Hennepin Healthcare Research Institute / Hennepin County Medical Center, Minneapolis, Minnesota, United States.
The study start date is October 13, 2020.
Consecutive patients presenting to the emergency department, in whom serial cTnI measurements are ordered on clinical indication at Hennepin Healthcare / Hennepin County Medical Center (Minneapolis, MN, USA) to rule-in and rule-out acute myocardial infarction can enrolled into this study.
Among the inclusion criteria are:
- Presents to the ED, or ambulatory care center equivalent, with signs or symptoms suspicious of a possible ACS event.
- Baseline cTn-I measurement and one additional cTn-I measurement at two hours after the first measurement.
- At least one 12-lead electrocardiogram.
This page provides a more detailed overview of this clinical trial: https://ichgcp.net/clinical-trials-registry/NCT04772157
